FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants, according to a news release issued by Johnson & Johnson.
Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...
Inquirer on MSN1d
Ketamine a lifeline for severe depression patients in SingaporeKetamine, the controlled drug best known as a horse tranquilizer or party supplement, has in the last four years become a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback